Exclusive Archives - Page 3 Of 23 - Investory Spot
Investory Spot
Skip to content
Trending News
May 2, 2025
How to Survive and Thrive When the Economy...
April 13, 2025
Money Matters: 7 Overlooked Financial Habits That Make...
February 26, 2025
Gold ETFs drew largest weekly inflow since March...
February 23, 2025
What is a REIT?
February 23, 2025
10 Best Beginners investment options
Investory Spot
News
Investory News
Property News
Funds
Commodities
Private Equity
Rates & Bonds
ETFs
Stocks
Money
Currencies
Loan
Tech News
Economics
Cryptocurrency News
Articles
Investment Promotion
Daily Investory News
Exclusive
Exclusive
Page 3

Category: Exclusive

The Best Stocks to Invest $50,000 in Right Now
Exclusive Investory News Stocks

The Best Stocks to Invest $50,000 in Right Now

Building an investment portfolio is like planning a vacation: You want to find the right balance between the places you know and some exciting surprises. And when it comes to…

the motley fool2 years ago
1168
0
54321
0 (0 votes)
Learn more
Bank of America remains confident in Salesforce following Dreamforce conference
Economics Exclusive Latest News Money Stocks

Bank of America remains confident in Salesforce following Dreamforce conference

Bank of America reiterated their Buy rating on Salesforce (NYSE:CRM) with a 12-month price target of $280.00 after attending the software company’s Dreamforce conference this week in San Francisco. During…

Investing.com2 years ago
811
0
54321
0 (0 votes)
Learn more
Shibarium is LIVE - Don't miss your opportunity to earn
Economics Exclusive Latest News Popular

Shibarium is LIVE - Don't miss your opportunity to earn

Crypto enthusiasts, the moment we’ve all been eagerly waiting for has arrived. Shibarium, a beacon of innovation in the decentralized finance space, has now launched its beta phase, and it’s…

investoryspot.com2 years ago
1164
0
54321
0 (0 votes)
Learn more
AstraZeneca's Tagrisso slashes death risk in certain post-surgery lung cancer patients
Exclusive Latest News Stocks

AstraZeneca's Tagrisso slashes death risk in certain post-surgery lung cancer patients

LONDON (Reuters) – AstraZeneca (NASDAQ:AZN)’s lung cancer therapy, Tagrisso, cut the risk of death by more than half in patients with a certain form of lung cancer who were diagnosed…

Reuters2 years ago
777
0
54321
0 (0 votes)
Learn more

Want to Advertise or Publish Article with us? Click Here

Promotion

Sign Up
For Newsletter

Hottest articles on your inbox!
Subscribe!
Recommended
How to Survive and Thrive When...
When the economy tightens...
Money Matters: 7 Overlooked Financial Habits...
Starting a business for...
Gold ETFs drew largest weekly inflow...
Physically backed gold exchange-traded...
Publications
Recent
Popular
Bugatti’s new $4 million Tourbillon has the wildest steering wheel ever
Bugatti’s new $4 million Tourbillon has the wildest...
Bitcoin price today: flat at $67k, more Fed cues in focus
Bitcoin price today: flat at $67k, more Fed...
Bitcoin investment
Bitcoin investment
Thales Directory
Web Directory
goldinvestment
How to Survive and Thrive When the Economy Takes a Dive
How to Survive and Thrive When...
Money Matters: 7 Overlooked Financial Habits That Make or Break First-Time Business Owners
Money Matters: 7 Overlooked Financial Habits...
Gold ETFs drew largest weekly inflow since March 2022
Gold ETFs drew largest weekly inflow...
Investory Spot
LEGAL INFO:
Disclaimer
Terms and Conditions
Privacy Policy
Navigation
News
Investory News
Property News
Commodities
Funds
Private Equity
Rates & Bonds
Stocks
ETFs
Currencies
Tech News
Economics
Cryptocurrency News
Articles
Stay Connected
  • Facebook
  • Twitter
  • Pinterest
  • Contact Us
Sign up for Newsletter

Hottest articles on your inbox!

Subscribe!

© Copyright 2020-2025. Investory Spot. All Rights Reserved


THE PURPOSE OF THIS WEBSITE IS TO PROVIDE INFORMATION AND EDUCATION TO INVESTORS. IT DOES NOT PROVIDE FINANCIAL ADVICE OR RECOMMENDATIONS TO BUY OR SELL SPECIFIC INVESTMENTS AND IS THEREFORE NOT REGULATED BY THE FINANCIAL CONDUCT AUTHORITY. IF YOU NEED FINANCIAL ADVICE YOU SHOULD CONSULT WITH A REGULATED FINANCIAL ADVISER.

Active Search Results